Assessing the role of Mac-2 binding protein glycosylation isomer in the management of patients with chronic hepatitis B

Table 2 Baseline major markers of 346 study participants in various fibrosis stages, median (interquartile range)/means ± SD

Variable	F0 (n = 37)	F1 (n = 83)	F2 (n = 105)	F3 (n = 48)	F4 (n = 73)	Overall P value (< 0.05)
Male/Female	12/25	40/43	69/36	31/17	54/19
Age (years)	37 ± 8.6	40 ± 10.8	41.1 ± 11.6	44.2 ± 12.0	48.1 ± 13.2	< 0.0001
Platelet (109/L)	232.0 (202.5-260)	235 (210-275)	212 (184.8-244.5)	191 (166.5-252.8)	167 (130.5-207.5)	< 0.0001
AST (IU/L)	21.8 (18.7-25.3)	23.4 (19.5-26.5)	34.4 (26.3-47.8)	40.1 (28.6-57.3)	45.0 (35.4-73.4)	< 0.0001
ALT (IU/L)	23.1 (14.6-26.9)	21.7 (16.4-27.1)	39.0 (27.6-67.4)	49.9 (37.0-76.3)	52.3 (33-73)	< 0.0001
Hemoglobin (g/L)	13.8 (13.1-15)	14.3 (13.5-15.5)	14.8 (13.9-15.9)	14.6 (13.7-16.2)	14.7 (13.7-16.1)	0.006
WBC (109/L)	6.4 (5.8-7.9)	6.5 (5.8-7.5)	6.7 (5.5-8.5)	6.8 (6.0-8.3)	6.5 (5.6-8.1)	0.621
Fibroscan (kPa)	4.6 (4-4.9)	6.0 (5.5-6.4)	7.8 (7.5-8.4)	10.5 (9.8-11.5)	22.3 (17.3-31.6)	< 0.0001
M2BPGi (C.O.I)	0.66 (0.51-1)	0.76 (0.51-1.01)	0.93 (0.74-1.34)	1.54 (1.13-1.94)	3.2 (1.56-3.9)	< 0.0001
FIB-4	0.74 (0.58-0.94)	0.83 (0.65-1.03)	1.08 (0.75-1.5)	1.28 (0.93-2.2)	2.18 (1.5-3.4)	< 0.0001
APRI	0.25 (0.21-0.31)	0.26 (0.21-0.33)	0.47 (0.34-0.72)	0.68 (0.43-1.1)	1.37 (0.69-3.19)	< 0.0001

AST: Aspartate transaminase; ALT: Alanine transaminase; WBC: White blood cell; C.O.I: Cut-off Index; FIB-4: Fibrosis-4 index; M2BPGi: Mac-2 binding protein glycosylated isomer; APRI: Aspartate transaminase to platelet ratio index.